We are live on ! Find out more

Adaptive Biotechnologies

ADPT

Market cap $4.53B

27.98 USD

+1.15

4.29%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

27.52

-0.46

1.64%

1 day

4.29%

5 days

3.71%

1 month

4.01%

3 months

18.56%

6 months

93.9%

Year to date

75.86%

1 year

79.82%

5 years

-23.34%

10 years

-30.57%

About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Employees: 624

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 23.1%

Neutral 76.9%

Negative 0%

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Adaptive Biotechnologies (ADPT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.15 per share a year ago.

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Zacks Investment Research

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies NASDAQ: ADPT reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development.

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026. “Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies.

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure

Adaptive Biotechnologies benefits from new NCCN guidelines and IMS cure definitions, positioning clonoSEQ as the standard for long-term myeloma MRD monitoring. MRD revenues grew 33% year-over-year to $66.2M, with clinical ASP up 7% and test volumes up 43%, driving adjusted EBITDA margin to 14%. Elimination of the OrbiMed revenue share and a $345M zero-coupon note refinancing provide ADPT with over five years of runway and remove a major growth tax.

Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure

Alger Small Cap Focus Fund Q3 2026 Portfolio Update

Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.

Alger Small Cap Focus Fund Q3 2026 Portfolio Update

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted significant updates to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma that further establish highly sensitive minimal (or measurable) residual disease (MRD) assessment as an important tool in myeloma care.

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

See News Rankings

Price charts implemented using Lightweight Charts™